REMARKS

The above amendment to the claim 1 is for the sole purpose of conforming the claims to the elected invention. Claim 11 has been cancelled as being in a "use" format inappropriate to U.S. practice. Pharmaceutical composition claim 10 has been amended to make it dependent on any one of claims 1-8. Method of treatment claim 12 has been amended and new claim 13 has been added to separate the recitations in original claim 12, of compounds of claim 1 and the specifically named compound, into separate claims. Claim 12 has also been amended to be dependent on any one of claims 1-8, and to be in a more customary format for U.S. practice. The amendments are made without waiver or prejudice to Applicant's right to prosecute the non-elected subject matter in one or more divisional applications. Entry of these amendments and a favorable action on these claims is respectfully requested.

The Examiner's attention is also called to the Information Disclosure Statement being filed herewith. It is respectfully requested that the reference accompanying this Information Disclosure Statement be considered when this application is acted on, and that such consideration be acknowledged by initialing and returning a copy of the accompanying Form PTO-1449. The Examiner is also reminded to take into consideration (and acknowledge such consideration) of the documents cited in the International Search Report and PTO-1449 filed with this application on September 20, 2001, and the related applications and documents cited in and filed with the Information Disclosure Statement and PTO-1449, filed and dated January 3, 2003.

Conclusion

Entry of the above amendments and a favorable action on the merits are respectfully requested, together with consideration of the cited documents of record in this application.

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: January 23, 2003 By: _____

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Morgan Lewis & Bockius LLP
Customer No. **009629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES

IN THE CLAIMS:

Claim 11 has been cancelled, and new claim 13 has been added.

Claims 1, 10 and 12 have been amended as follows, without prejudice, wherein deleted material is shown by **[bold text within brackets]** and added material is shown by **bold underlined text**:

1. (Amended) A bicyclic compound of the Formula (I):



(I)

wherein:

G is N**[, CH or C(CN)]**;

ring X is a 5- or 6-membered fused heteroaryl ring which contains 1, 2 or 3 heteroatoms selected from oxygen, sulphur and nitrogen;

m is 0, 1 or 2;

R^1 is hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, -O-(C_{1-3}alkyl)-O-, C_{1-6}alkylS(O)$_n$- (wherein n is 0-2), *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkoxycarbonyl, *N*-C_{1-6}alkylcarbamoyl, *N*,*N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{2-6}alkanoyl, C_{1-6}alkanoyloxy, C_{1-6}alkanoylamino, *N*-C_{1-6}alkylsulphamoyl, *N*,*N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino, C_{1-6}alkylsulphonyl-*N*-(C_{1-6}alkyl)amino, or R^1 is of the Formula (IA):

$$A-(CH_2)_p-B- \qquad (IA)$$

wherein A is halo, hydroxy, C_{1-6}alkoxy, C_{1-6}alkylS(O)$_n$- (wherein n is 0-2), cyano, amino, *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino, carboxy, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-C_{1-6}alkylcarbamoyl or *N*,*N*-(C_{1-6}alkyl)$_2$carbamoyl, p is 1 - 6, and B is a bond, oxy, imino, *N*-(C_{1-6}alkyl)imino or -C(O)NH-, with the proviso that p is 2 or more unless B is a bond or -C(O)NH-,

or R^1 is of the Formula (IB):

$$D—E— \qquad (IB)$$

wherein D is aryl, heteroaryl or heterocyclyl and E is a bond, C_{1-6}alkylene, C_{1-6}alkyleneoxy, oxy, imino, *N*-(C_{1-6}alkyl)imino, C_{1-6}alkyleneimino, *N*-(C_{1-6}alkyl)-C_{1-6}alkyleneimino, C_{1-6}alkyleneoxy-C_{1-6}alkylene, C_{1-6}alkyleneimino-C_{1-6}alkylene, *N*-(C_{1-6}alkyl)-C_{1-6}alkyleneimino-C_{1-6}alkylene, -C(O)NH-, -SO_2NH-, -NHSO_2- or C_{2-6}alkanoylimino,

and any aryl, heteroaryl or heterocyclyl group in a R^1 group may be optionally substituted with one or more groups selected from hydroxy, halo, C_{1-6}alkyl, C_{1-6}alkoxy, carboxy, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-C_{1-6}alkylcarbamoyl, *N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{2-6}alkanoyl, amino, *N*-C_{1-6}alkylamino and *N*,*N*-(C_{1-6}alkyl)$_2$amino,

and any heterocyclyl group in a R^1 group may be optionally substituted with one or two oxo or thioxo substituents,

and any of the R^1 groups defined hereinbefore which comprises a CH_2 group which is attached to 2 carbon atoms or a CH_3 group which is attached to a carbon atom may optionally bear on each said CH_2 or CH_3 group a substituent selected from hydroxy, amino, C_{1-6}alkoxy, *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino and heterocyclyl;

R^2 is hydrogen, halo, C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl;

R^3 is hydrogen, halo, C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl;

R^4 is hydrogen, hydroxy, C_{1-6}alkyl, C_{1-6}alkoxy, amino, *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino, hydroxyC_{2-6}alkoxy, C_{1-6}alkoxyC_{2-6}alkoxy, aminoC_{2-6}alkoxy, *N*-C_{1-6}alkylaminoC_{2-6}alkoxy, *N*,*N*-(C_{1-6}alkyl)$_2$aminoC_{2-6}alkoxy or C_{3-7}cycloalkyl,

or R^4 is of the Formula (IC):

—K—J (IC)

wherein J is aryl, heteroaryl or heterocyclyl and K is a bond, oxy, imino, *N*-(C_{1-6}alkyl)imino, oxyC_{1-6}alkylene, iminoC_{1-6}alkylene, *N*-(C_{1-6}alkyl)iminoC_{1-6}alkylene, -NHC(O) -, -SO_2NH-, -NHSO_2- or -NHC(O)-C_{1-6}alkylene-,

and any aryl, heteroaryl or heterocyclyl group in a R^4 group may be optionally substituted by one or more groups selected from hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, -O-(C_{1-3}alkyl)-O-, C_{1-6}alkylS(O)$_n$- (wherein n is 0-2), *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkoxycarbonyl, *N*-C_{1-6}alkylcarbamoyl, *N*,*N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{2-6}alkanoyl, C_{1-6}alkanoyloxy, C_{1-6}alkanoylamino, *N*-C_{1-6}alkylsulphamoyl, *N*,*N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino and C_{1-6}alkylsulphonyl-*N*-(C_{1-6}alkyl)amino,

or any aryl, heteroaryl or heterocyclyl group in a R^4 group may be optionally substituted with one or more groups of the Formula (IA'):

$$-B^1-(CH_2)_p-A^1 \qquad \text{(IA')}$$

wherein A^1 is halo, hydroxy, C_{1-6}alkoxy, cyano, amino, *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino, carboxy, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-C_{1-6}alkylcarbamoyl or *N*,*N*-(C_{1-6}alkyl)$_2$carbamoyl, p is 1 - 6, and B^1 is a bond, oxy, imino, *N*-(C_{1-6}alkyl)imino or -NHC(O)-, with the proviso that p is 2 or more unless B^1 is a bond or -NHC(O)-,

or any aryl, heteroaryl or heterocyclyl group in a R^4 group may be optionally substituted with one or more groups of the Formula (IB'):

$$-E^1-D^1 \qquad \text{(IB')}$$

wherein D^1 is aryl, heteroaryl or heterocyclyl and E^1 is a bond, C_{1-6}alkylene, oxyC_{1-6}alkylene, oxy, imino, *N*-(C_{1-6}alkyl)imino, iminoC_{1-6}alkylene, *N*-(C_{1-6}alkyl)-iminoC_{1-6}alkylene, C_{1-6}alkylene-oxyC_{1-6}alkylene, C_{1-6}alkylene-iminoC_{1-6}alkylene, C_{1-6}alkylene-*N*-(C_{1-6}alkyl)-iminoC_{1-6}alkylene, -NHC(O)-, -NHSO_2-, -SO_2NH- or -NHC(O)-C_{1-6}alkylene-,

and any aryl, heteroaryl or heterocyclyl group in a substituent on R^4 may be optionally substituted with one or more groups selected from hydroxy, halo, C_{1-6}alkyl, C_{1-6}alkoxy,

carboxy, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-C_{1-6}alkylcarbamoyl, *N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{2-6}alkanoyl, amino, *N*-C_{1-6}alkylamino and *N,N*-(C_{1-6}alkyl)$_2$amino,

and any C_{3-7}cycloalkyl or heterocyclyl group in a R^4 group may be optionally substituted with one or two oxo or thioxo substituents,

and any of the R^4 groups defined hereinbefore which comprises a CH_2 group which is attached to 2 carbon atoms or a CH_3 group which is attached to a carbon atom may optionally bear on each said CH_2 or CH_3 group a substituent selected from hydroxy, amino, C_{1-6}alkoxy, *N*-C_{1-6}alkylamino, *N,N*-(C_{1-6}alkyl)$_2$amino and heterocyclyl;

R^5 is hydrogen, halo, trifluoromethyl, cyano, nitro, amino, hydroxy, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, *N*-C_{1-6}alkylamino or *N,N*-(C_{1-6}alkyl)$_2$amino;

q is 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof;

with the proviso that 7-amino-4-(3-acetamidoanilino)pyrido[4,3-*d*]pyrimidine is excluded.

10. (Amended) A pharmaceutical composition which comprises a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or *in vivo* cleavable ester thereof, according to **[claim 1]** **any one of claims 1-8** in association with a pharmaceutically acceptable diluent or carrier.

12. (Amended) A method of **[of]** treating **a disease** **[diseases]** or medical **condition** **[conditions]** mediated by cytokines which comprises administering to a warm-blooded animal **in need thereof** an effective amount of a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to **any one of claims 1-8.** **[claim 1 or of the compound 7-amino-4-(3-acetamidoanilino)pyrido[4,3-*d*]pyrimidine.]**